Trial Profile
An Open-label, Randomised, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Characteristics, Safety and Tolerability of up to Two Formulations (With Different Taste Masking Approaches) of an Orally Disintegrating Tablet (ODT) of Lamotrigine at 25mg and 200mg Versus the Immediate Release (IR) Lamotrigine in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Lamotrigine (Primary)
- Indications Bipolar disorders; Lennox-Gastaut syndrome; Partial epilepsies; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- Sponsors GSK
- 04 Jan 2007 New trial record.